Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2911

A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 2895

Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish

9:00AM-11:00AM: Abstract Number: 2915

An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs

9:00AM-11:00AM: Abstract Number: 2898

Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis: Is Empiric Use of Proton Pump Inhibitors Supported?

9:00AM-11:00AM: Abstract Number: 2908

Anti-Vinculin Antibodies: A Novel Biomarker in Systemic Sclerosis, and Its Association with Vascular Involvement

9:00AM-11:00AM: Abstract Number: 2914

Association of Radiographic Findings in Hand X-Ray with Autoantibodies in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2909

Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2887

Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2922

Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2890

Feasibility of Same Day Adipose Tissue Harvest, Cell Processing and Subcutaneous Delivery of Adipose Derived Regenerative Cells into Fingers of Scleroderma Patients within a Randomized Double Blind Clinical Trial

9:00AM-11:00AM: Abstract Number: 2913

Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2899

Impact of the Clinical Characteristics of Systemic Sclerosis in Patients Quality of Life

9:00AM-11:00AM: Abstract Number: 2897

Microvascular Function in Systemic Sclerosis Patients with End-Stage Vascular Manifestations of the Disease

9:00AM-11:00AM: Abstract Number: 2917

Nailfold Capillaroscopy and Mortality in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2921

Patient Participation in Patient Reported Outcome Instrument Development in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2912

Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)

9:00AM-11:00AM: Abstract Number: 2905

Predictors of Poor Hand Function in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2902

Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group

9:00AM-11:00AM: Abstract Number: 2919

Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort

9:00AM-11:00AM: Abstract Number: 2891

Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study

9:00AM-11:00AM: Abstract Number: 2904

Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients

9:00AM-11:00AM: Abstract Number: 2896

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers

9:00AM-11:00AM: Abstract Number: 2907

Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)

9:00AM-11:00AM: Abstract Number: 2892

Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low

9:00AM-11:00AM: Abstract Number: 2901

SSc and the Significance of Blood Group Antigens

9:00AM-11:00AM: Abstract Number: 2918

The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2920

The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey

9:00AM-11:00AM: Abstract Number: 2916

The Number of Micro-Haemorrhages and Micro-Thrombosis Detected By Nailfold Videocapillaroscopy Is a Good Predictor of Disease Activity in Systemic Sclerosis: The Validation Study of NEMO Score

9:00AM-11:00AM: Abstract Number: 2906

The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience

9:00AM-11:00AM: Abstract Number: 2889

Therapeutic Plasma Exchange for the Treatment of Raynaud’s and Digital Ulcers in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2903

Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up

9:00AM-11:00AM: Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2910

Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].